– Presentation at SLEEP 2026 illustrates ability to convert non-responders into responders using personalized programming LONDON --(BUSINESS WIRE)--Jun. 16, 2026-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced new data showing that use of its PolySync™
LONDON --(BUSINESS WIRE)--Jun. 11, 2026-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced the election of Jette Nygaard-Andersen to the Company’s Board of Directors after its Annual General Meeting of shareholders on June 10.
LONDON --(BUSINESS WIRE)--Jun. 5, 2026-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the appointment of Anne Liddy as Chief Legal Officer, effective August 31. Liddy will oversee the Company’s global legal and compliance function and serve as a member
LONDON --(BUSINESS WIRE)--May 21, 2026-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Stefano Folli will join the Company as incoming President, Cardiopulmonary (CP), effective June 1, succeeding Franco Poletti, who will retire on July 31.
LONDON --(BUSINESS WIRE)--May 19, 2026-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the Goldman Sachs 47 th Annual Global Healthcare Conference in Miami Beach, Fla. Vladimir Makatsaria, Chief Executive Officer of LivaNova; Alex
– Delivered double-digit reported and constant-currency revenue growth – Raised full-year 2026 revenue and adjusted diluted earnings per share guidance (1) – Received U.S. Food and Drug Administration premarket approval for aura6000 System to treat moderate to severe obstructive sleep apnea LONDON
– Study demonstrates proximal hypoglossal nerve stimulation (pHGNS) yielded clinically significant responses and sustained improvements over time – First rigorous RCT study design in HGNS space supports pHGNS becoming a competitive option in the treatment landscape LONDON --(BUSINESS WIRE)--Apr.
LONDON --(BUSINESS WIRE)--Mar. 25, 2026-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2026 results on Wed., May 6, 2026, at 1 p.m. London time ( 8 a.m. Eastern Daylight Time).
– First and only hypoglossal nerve stimulation therapy approved in the U.S. without complete concentric collapse contraindication or warning language – Next-generation, MRI-compatible device expected to launch in the first half of 2027, pending FDA supplement review LONDON --(BUSINESS WIRE)--Mar.
– Delivered double-digit reported and organic revenue growth and continued operating margin expansion for full-year 2025 – Issued full-year 2026 guidance, including constant-currency revenue growth between 6.0% and 7.0% and adjusted diluted earnings per share in the range of $4.15 to $4.25 –
LONDON --(BUSINESS WIRE)--Jan. 20, 2026-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2025 results on Wed., Feb. 25, 2026 , at 1 p.m. London time ( 8 a.m. Eastern Standard Time ).